Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.40
NAS:AKRX's Cash-to-Debt is ranked lower than
73% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:AKRX: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.35 Max: No Debt
Current: 0.4
Equity-to-Asset 0.44
NAS:AKRX's Equity-to-Asset is ranked lower than
77% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:AKRX: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.54 Max: 0.95
Current: 0.44
0.1
0.95
Interest Coverage 6.02
NAS:AKRX's Interest Coverage is ranked lower than
77% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. NAS:AKRX: 6.02 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 1.71  Med: 7.4 Max: No Debt
Current: 6.02
Piotroski F-Score: 5
Altman Z-Score: 3.66
Beneish M-Score: -2.97
WACC vs ROIC
10.39%
10.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 23.23
NAS:AKRX's Operating Margin % is ranked higher than
91% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:AKRX: 23.23 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKRX' s Operating Margin % Range Over the Past 10 Years
Min: -37.46  Med: 17.96 Max: 29.91
Current: 23.23
-37.46
29.91
Net Margin % 12.15
NAS:AKRX's Net Margin % is ranked higher than
80% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:AKRX: 12.15 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKRX' s Net Margin % Range Over the Past 10 Years
Min: -36.24  Med: 14.56 Max: 31.41
Current: 12.15
-36.24
31.41
ROE % 14.88
NAS:AKRX's ROE % is ranked higher than
86% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:AKRX: 14.88 )
Ranked among companies with meaningful ROE % only.
NAS:AKRX' s ROE % Range Over the Past 10 Years
Min: -50.57  Med: 21.2 Max: 35.12
Current: 14.88
-50.57
35.12
ROA % 6.28
NAS:AKRX's ROA % is ranked higher than
76% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:AKRX: 6.28 )
Ranked among companies with meaningful ROA % only.
NAS:AKRX' s ROA % Range Over the Past 10 Years
Min: -33.5  Med: 8.42 Max: 24.27
Current: 6.28
-33.5
24.27
ROC (Joel Greenblatt) % 45.51
NAS:AKRX's ROC (Joel Greenblatt) % is ranked higher than
88% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NAS:AKRX: 45.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.35  Med: 56.63 Max: 77.64
Current: 45.51
-48.35
77.64
3-Year Revenue Growth Rate 47.10
NAS:AKRX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NAS:AKRX: 47.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AKRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 10.6 Max: 56.6
Current: 47.1
-37.1
56.6
3-Year EBITDA Growth Rate 54.10
NAS:AKRX's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:AKRX: 54.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AKRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.8 Max: 149.9
Current: 54.1
0
149.9
3-Year EPS without NRI Growth Rate 47.30
NAS:AKRX's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:AKRX: 47.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AKRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: 18.6 Max: 93.1
Current: 47.3
-50.4
93.1
GuruFocus has detected 4 Warning Signs with Akorn Inc $NAS:AKRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKRX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AKRX Guru Trades in Q3 2016

Richard Snow 149,070 sh (New)
Lee Ainslie 116,040 sh (New)
Paul Tudor Jones 31,282 sh (+1.68%)
Mario Gabelli 44,600 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Steven Cohen Sold Out
John Paulson 8,974,400 sh (-0.43%)
Murray Stahl 14,766 sh (-1.74%)
Joel Greenblatt 227,948 sh (-43.55%)
Columbia Wanger 1,064,814 sh (-48.72%)
» More
Q4 2016

AKRX Guru Trades in Q4 2016

Steven Cohen 315,200 sh (New)
David Dreman 18,498 sh (New)
First Pacific Advisors 136,990 sh (New)
Richard Snow 376,150 sh (+152.33%)
Murray Stahl 19,927 sh (+34.95%)
Lee Ainslie 151,370 sh (+30.45%)
Mario Gabelli 56,900 sh (+27.58%)
Paul Tudor Jones 37,381 sh (+19.50%)
Columbia Wanger 1,179,455 sh (+10.77%)
John Paulson 8,686,500 sh (-3.21%)
Joel Greenblatt 145,407 sh (-36.21%)
» More
Q1 2017

AKRX Guru Trades in Q1 2017

Robert Olstein 228,900 sh (New)
FPA Capital Fund 380,120 sh (New)
First Pacific Advisors 775,680 sh (+466.23%)
Columbia Wanger 2,682,821 sh (+127.46%)
Mario Gabelli 65,300 sh (+14.76%)
David Dreman 18,498 sh (unchged)
Steven Cohen Sold Out
John Paulson 8,397,100 sh (-3.33%)
Murray Stahl 18,170 sh (-8.82%)
Lee Ainslie 131,770 sh (-12.95%)
Richard Snow 283,460 sh (-24.64%)
Joel Greenblatt 61,233 sh (-57.89%)
Paul Tudor Jones 8,400 sh (-77.53%)
» More
Q2 2017

AKRX Guru Trades in Q2 2017

Jim Simons 909,904 sh (New)
Paul Tudor Jones 375,000 sh (+4364.29%)
Mario Gabelli 276,825 sh (+323.93%)
Joel Greenblatt 218,027 sh (+256.06%)
David Dreman Sold Out
Columbia Wanger Sold Out
Richard Snow Sold Out
FPA Capital Fund Sold Out
First Pacific Advisors Sold Out
Robert Olstein Sold Out
John Paulson Sold Out
Murray Stahl 11,935 sh (-34.31%)
Lee Ainslie 71,220 sh (-45.95%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Add 323.93%0.05%$23.33 - $33.58 $ 31.98-1%276,825
Joel Greenblatt 2017-06-30 Add 256.06%0.07%$23.33 - $33.58 $ 31.98-1%218,027
David Dreman 2017-06-30 Sold Out 0.25%$23.33 - $33.58 $ 31.98-1%0
John Paulson 2017-06-30 Sold Out 2.7%$23.33 - $33.58 $ 31.98-1%0
Robert Olstein 2017-06-30 Sold Out 0.71%$23.33 - $33.58 $ 31.98-1%0
FPA Capital Fund 2017-06-30 Sold Out 1.83%$23.33 - $33.58 $ 31.98-1%0
John Paulson 2017-03-31 Reduce -3.33%0.08%$18.29 - $24.77 $ 31.9847%8,397,100
FPA Capital Fund 2017-03-31 New Buy1.83%$18.29 - $24.77 $ 31.9847%380,120
Robert Olstein 2017-03-31 New Buy0.71%$18.29 - $24.77 $ 31.9847%228,900
Mario Gabelli 2017-03-31 Add 14.76%$18.29 - $24.77 $ 31.9847%65,300
Joel Greenblatt 2017-03-31 Reduce -57.89%0.02%$18.29 - $24.77 $ 31.9847%61,233
John Paulson 2016-12-31 Reduce -3.21%0.09%$18.23 - $28.13 $ 31.9839%8,686,500
Joel Greenblatt 2016-12-31 Reduce -36.21%0.03%$18.23 - $28.13 $ 31.9839%145,407
Mario Gabelli 2016-12-31 Add 27.58%$18.23 - $28.13 $ 31.9839%56,900
David Dreman 2016-12-31 New Buy0.23%$18.23 - $28.13 $ 31.9839%18,498
John Paulson 2016-09-30 Reduce -0.43%0.01%$26.46 - $34.23 $ 31.988%8,974,400
Joel Greenblatt 2016-09-30 Reduce -43.55%0.06%$26.46 - $34.23 $ 31.988%227,948
George Soros 2016-09-30 Sold Out 0.03%$26.46 - $34.23 $ 31.988%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:CTLT, NAS:OPK, NAS:MDCO, NAS:IRWD, NAS:SUPN, NAS:PAHC, NAS:RDUS, NAS:PCRX, NAS:IPXL, NAS:MNTA, NYSE:DPLO, NAS:HRTX, NAS:EGRX, NAS:FLXN, NAS:AMPH, NAS:SGYP, NYSE:LCI, NAS:SCLN, NAS:ACET, NAS:SCMP » details
Traded in other countries:FDA.Germany,
Headquarter Location:USA
Akorn Inc is a United States based generic pharmaceutical company. It develops, manufactures and markets generic and branded prescription pharmaceuticals as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Top Ranked Articles about Akorn Inc

Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi
Johnson & Weaver, Announces Investigations of Omega Protein Corporation, Monogram Residential Trust, Inc. and Akorn, Inc.; Investors Encouraged to Contact Firm
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akorn, Inc. (AKRX)
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX
Robert Olstein's Largest 1st-Quarter Buys Alphabet, Hormel, ExxonMobil on the list
Robert Olstein (Trades, Portfolio) is the chairman and chief investment officer of the Olstein Financial Alert Fund. During the first quarter the guru bought shares in the following stocks: Read more...
Lifshitz & Miller LLP Announces Investigation of AdvancePierre Foods Holdings, Inc., Akorn, Inc., AllianceMMA, Inc., Altisource Portfolio Solutions, DelTaco Restaurants, Inc., Express Scripts Holding Company, China Unicom (Hong Kong) Limited, and Global E
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akorn, Inc.
Harwood Feffer LLP Announces Investigation of Akorn, Inc.
AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price?
FPA Capital Buys 2 Beaten-Down Stocks, Energy in Fourth Quarter Fund buys stocks at low points
FPA Capital released its first portfolio update of 2017, disclosing purchase of two new positions and a raft of oil and gas stocks as it adhered to its guideline of selling equities that approach intrinsic value and buying those with a margin of safety and price discount to intrinsic value. Read more...

Ratios

vs
industry
vs
history
PE Ratio 32.30
AKRX's PE Ratio is ranked higher than
61% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. AKRX: 32.30 )
Ranked among companies with meaningful PE Ratio only.
AKRX' s PE Ratio Range Over the Past 10 Years
Min: 12.14  Med: 33.82 Max: 495
Current: 32.3
12.14
495
Forward PE Ratio 20.24
AKRX's Forward PE Ratio is ranked lower than
58% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. AKRX: 20.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.30
AKRX's PE Ratio without NRI is ranked higher than
61% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.21 vs. AKRX: 32.30 )
Ranked among companies with meaningful PE Ratio without NRI only.
AKRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.14  Med: 33.82 Max: 495
Current: 32.3
12.14
495
Price-to-Owner-Earnings 21.71
AKRX's Price-to-Owner-Earnings is ranked higher than
67% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. AKRX: 21.71 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AKRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.08  Med: 50.17 Max: 332.16
Current: 21.71
11.08
332.16
PB Ratio 4.51
AKRX's PB Ratio is ranked lower than
73% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. AKRX: 4.51 )
Ranked among companies with meaningful PB Ratio only.
AKRX' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.42 Max: 16.87
Current: 4.51
1.42
16.87
PS Ratio 3.93
AKRX's PS Ratio is ranked lower than
58% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. AKRX: 3.93 )
Ranked among companies with meaningful PS Ratio only.
AKRX' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 6.19 Max: 12.98
Current: 3.93
0.75
12.98
Price-to-Free-Cash-Flow 20.45
AKRX's Price-to-Free-Cash-Flow is ranked higher than
59% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. AKRX: 20.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 76.89 Max: 2950
Current: 20.45
10.51
2950
Price-to-Operating-Cash-Flow 13.73
AKRX's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. AKRX: 13.73 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.08  Med: 46.33 Max: 192.86
Current: 13.73
9.08
192.86
EV-to-EBIT 18.92
AKRX's EV-to-EBIT is ranked higher than
67% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. AKRX: 18.92 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -186.6  Med: 15.3 Max: 213.1
Current: 18.92
-186.6
213.1
EV-to-EBITDA 13.88
AKRX's EV-to-EBITDA is ranked higher than
71% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. AKRX: 13.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -560.8  Med: 14.5 Max: 2955.7
Current: 13.88
-560.8
2955.7
PEG Ratio 0.66
AKRX's PEG Ratio is ranked higher than
91% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. AKRX: 0.66 )
Ranked among companies with meaningful PEG Ratio only.
AKRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.42 Max: 0.68
Current: 0.66
0.06
0.68
Shiller PE Ratio 75.61
AKRX's Shiller PE Ratio is ranked lower than
78% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. AKRX: 75.61 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 50.27  Med: 110.32 Max: 2690.5
Current: 75.61
50.27
2690.5
Current Ratio 5.46
AKRX's Current Ratio is ranked higher than
72% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AKRX: 5.46 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.42 Max: 17
Current: 5.46
0.21
17
Quick Ratio 4.05
AKRX's Quick Ratio is ranked higher than
70% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. AKRX: 4.05 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.35 Max: 12.29
Current: 4.05
0.02
12.29
Days Inventory 152.61
AKRX's Days Inventory is ranked lower than
66% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. AKRX: 152.61 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 118.8  Med: 148.93 Max: 188.37
Current: 152.61
118.8
188.37
Days Sales Outstanding 63.53
AKRX's Days Sales Outstanding is ranked lower than
52% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. AKRX: 63.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.46  Med: 61.64 Max: 123.33
Current: 63.53
25.46
123.33
Days Payable 36.41
AKRX's Days Payable is ranked lower than
77% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. AKRX: 36.41 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 53.34 Max: 123.76
Current: 36.41
19.92
123.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
AKRX's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. AKRX: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -4.6 Max: 1.2
Current: -8.8
-63.1
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.99
AKRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AKRX: 1.99 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AKRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.51  Med: 9.85 Max: 749
Current: 1.99
1.51
749
Price-to-Median-PS-Value 0.63
AKRX's Price-to-Median-PS-Value is ranked higher than
88% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. AKRX: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.28 Max: 1.96
Current: 0.63
0.04
1.96
Price-to-Peter-Lynch-Fair-Value 1.29
AKRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
75% of the 207 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. AKRX: 1.29 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AKRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.03 Max: 2.77
Current: 1.29
0.47
2.77
Earnings Yield (Greenblatt) % 5.29
AKRX's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AKRX: 5.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.6  Med: 2.7 Max: 11.2
Current: 5.29
-19.6
11.2
Forward Rate of Return (Yacktman) % 52.47
AKRX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. AKRX: 52.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: -0.7 Max: 1017.5
Current: 52.47
-15.5
1017.5

More Statistics

Revenue (TTM) (Mil) $1,020.32
EPS (TTM) $ 0.99
Beta1.65
Short Percentage of Float10.03%
52-Week Range $17.61 - 34.00
Shares Outstanding (Mil)124.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 988 1,021 1,058
EPS ($) 1.45 1.53 1.54
EPS without NRI ($) 1.45 1.53 1.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AKRX

Headlines

Articles On GuruFocus.com
Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi Jul 19 2017 
Johnson & Weaver, Announces Investigations of Omega Protein Corporation, Monogram Residential Trust, Jul 07 2017 
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akorn, Inc. (AKRX) Jun 02 2017 
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX May 23 2017 
7 Stocks With Rising Prices and Margins of Safety May 17 2017 
Robert Olstein's Largest 1st-Quarter Buys May 11 2017 
Lifshitz & Miller LLP Announces Investigation of AdvancePierre Foods Holdings, Inc., Akorn, Inc., Al Apr 28 2017 
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigate Apr 25 2017 
Harwood Feffer LLP Announces Investigation of Akorn, Inc. Apr 25 2017 
AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price? Apr 25 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Akorn Inc. Aug 16 2017
ETFs with exposure to Akorn, Inc. : August 15, 2017 Aug 15 2017
IHS Markit Score downgrades Akorn Inc to 21 out of 100, ranking positively in only one out of three... Aug 11 2017
Akorn, Inc. :AKRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017 Aug 02 2017
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : August 2, 2017 Aug 02 2017
Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi Jul 19 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jul 11 2017
Johnson & Weaver, Announces Investigations of Omega Protein Corporation, Monogram Residential Trust,... Jul 07 2017
ETFs with exposure to Akorn, Inc. : July 3, 2017 Jul 03 2017
Top 3 Companies Owned by Valeant (VRX) Jun 29 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc. (AKRX) Jun 29 2017
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Akorn, Inc. Jun 22 2017
ETFs with exposure to Akorn, Inc. : June 19, 2017 Jun 19 2017
Akorn, Inc. :AKRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX May 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}